Statement: Urosepsis was the most common adverse event in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 3/12 (25.00%)   Atrial fibrillation 0/12 (0.00%)   Cardiac ischemia/infarction  [1]0/12 (0.00%)   Congestive Heart Failure  [2]0/12 (0.00%)   Diverticulitis 0/12 (0.00%)   Cholecystitis 0/12 (0.00%)   Hyperbilirubinemia 0/12 (0.00%)   Urosepsis 2/12 (16.67%)   Brain hemorrhage complicating CNS metastasis 1/12 (8.33%)   Rash  [3]0/12 (0.00%)